The Tribunal de Justiça da União Europeia is moving closer to ruling that Brussels violated transparency obligations when it withheld key information about its COVID-19 vaccine contracts—a decision with direct implications for anyone in Portugal or the broader EU who wants to understand how public funds were spent and whether pharmaceutical firms received excessive legal protection at taxpayers' expense.
Why This Matters
• Public accountability wins: Advocate General Athanasios Rantos has recommended upholding lower-court rulings that the European Commission failed to provide adequate public access to vaccine negotiation documents.
• Hidden clauses exposed: The case centers on indemnity clauses that shifted liability for vaccine side effects from manufacturers to EU member states—including Portugal—and on the identities of negotiators whose conflicts of interest were never disclosed.
• Legal precedent ahead: While the advocate general's opinion is non-binding, the TJUE's final judgment will set the standard for future health-emergency procurements across the bloc.
What the Ruling Could Unmask
At the heart of the dispute are two categories of documents that the Comissão Europeia sought to keep under wraps. First, the declarations of no conflict of interest filed by members of the joint negotiating team—a mix of Commission officials and national experts who struck advance-purchase agreements with pharmaceutical companies in 2021. Second, contractual clauses on indemnification that determined which party would bear the cost if vaccines caused harm.
When members of the Parlamento Europeu and private citizens filed access requests under EU transparency law in 2021, Brussels granted only partial disclosure. It redacted negotiators' names—citing privacy and the risk of harassment by anti-vaccination activists—and blacked out entire sections of the liability terms, arguing that commercial interests of the pharmaceutical firms would suffer.
That stance collapsed in July 2024, when the Tribunal Geral da União Europeia issued two judgments declaring the Commission's redactions unlawful. The court found no evidence that revealing indemnity terms would spur "strategic abuse" or inflate litigation risk for drugmakers. It also ruled that public interest in verifying conflicts of interest outweighed the privacy claims of civil servants involved in multibillion-euro public procurements.
Advocate General Strengthens the Lower Court's Position
On June 11, 2026, Rantos delivered his formal opinion to the TJUE, recommending that the top court reject the Commission's appeals. He concluded that transparency in vaccine negotiations constitutes a specific public-interest objective under EU law—a threshold that overrides routine data-protection defenses.
On the liability clauses, Rantos noted that the Commission failed to demonstrate concrete harm to the pharmaceutical companies. Without proof that disclosure would invite predatory litigation or undermine future negotiations, the advocate general saw no legal basis for secrecy. His opinion signals that member-state governments—including the Portugal Cabinet—have a right to know exactly what financial and legal risks they assumed when they authorized emergency-use vaccines under EU-wide contracts.
How Portugal and Other Member States Ended Up Holding the Bag
During the pandemic, the União Europeia established a centralized procurement mechanism to ensure rapid, equitable vaccine access across all 27 member states. The Commission formed a joint negotiating team and signed advance-purchase agreements with manufacturers such as Pfizer-BioNTech, Moderna, and AstraZeneca.
Pharmaceutical industry lobbying was intense. The Vaccines Europe division of the Federação Europeia das Associações e Indústrias Farmacêuticas warned that unprecedented development timelines created "inevitable" risks and that the evidence base was thinner than in standard approval processes. In response, the contracts stipulated that vaccines would be administered under "epidemic conditions" and that their use was the "exclusive responsibility of participating member states."
Under EU emergency-authorization rules, when a member state recommends or mandates the use of a product granted conditional marketing approval, it must waive the manufacturer's civil and administrative liability. In practice, this meant that if a vaccine caused injury, the claim would be directed at national health authorities—INFARMED in Portugal's case—rather than at the company that produced it.
The financial exposure is not trivial. While manufacturers can request compensation from the Commission to defend or settle patient claims, the ultimate fiscal burden rests with national treasuries. For Portugal, which has already faced budget pressures from pandemic-related spending, understanding the precise wording of these indemnity clauses is essential for forecasting contingent liabilities and preparing legal defenses.
What This Means for Residents and Investors
If the TJUE follows the advocate general's recommendation, the ruling will compel the Comissão Europeia to release previously redacted sections of the vaccine contracts. That disclosure will allow Portuguese taxpayers, journalists, and civil-society organizations to scrutinize:
Conflict-of-interest declarations: Did any negotiator have prior or parallel ties to pharmaceutical companies, consulting firms, or lobby groups?
Indemnity caps and triggers: Under what circumstances can drugmakers invoke the liability shield, and are there monetary ceilings on member-state exposure?
Pricing and volume commitments: Transparency advocates have long suspected that the urgency of the pandemic allowed manufacturers to negotiate higher per-dose prices and minimum-purchase guarantees that locked governments into surplus inventory.
For residents of Portugal, greater transparency means more informed debate about public-health governance and fiscal risk. For foreign investors and multinational corporations operating here, the case serves as a reminder that EU procurement law—even in emergencies—cannot indefinitely override transparency obligations enshrined in the treaties.
Broader Implications for Health-Emergency Preparedness
The vaccine-transparency saga has already influenced new EU legislation. The Critical Medicines Act, with a political agreement finalized in May 2026, introduces binding principles of transparency, solidarity, and proportionality for national stockpiling of essential drugs. It also mandates information-sharing among member states—a direct response to the fragmented, opaque approach taken during the COVID-19 crisis.
Portugal is currently drafting regulations to establish a strategic pharmaceutical reserve in line with the new act. The lessons from the vaccine contracts—particularly the fiscal and legal pitfalls of liability waivers—are informing how Lisbon negotiates future emergency procurements with manufacturers.
Meanwhile, the broader pharmaceutical-pricing debate continues. Final prices paid by national agencies such as INFARMED remain confidential under most drug reimbursement agreements, preventing benchmarking and market intelligence. Patient advocates and health economists argue that the same public-interest rationale underpinning the vaccine-transparency cases should extend to all publicly funded medicines.
Timeline and Next Steps
The TJUE is expected to issue its final judgment in the coming months. Advocate general opinions are persuasive but not binding; however, the court follows them in roughly 70% to 80% of cases. If Brussels loses, it will be required to produce unredacted versions of the contested documents within a specified deadline.
Should the Commission comply, Portuguese citizens will gain access to a detailed record of how EU vaccine spending was allocated and on what legal terms. Estimates suggest Portugal's proportional share of the joint procurement reached several billion euros. If the Commission resists, further contempt-of-court proceedings could follow, along with potential financial penalties.
The Bigger Picture
The COVID-19 pandemic, declared by the Organização Mundial de Saúde in March 2020 and officially concluded in May 2023, resulted in more than 775 million confirmed infections worldwide and approximately 7 million deaths. In Portugal, health authorities recorded over 5 million cases and more than 26,000 deaths, making the crisis the most severe public-health emergency in modern Portuguese history.
The vaccine rollout—swift by any standard—was also the most expensive and legally complex pharmaceutical intervention the EU has ever undertaken. Whether the secrecy surrounding those contracts was justified by genuine commercial sensitivity or simply by bureaucratic reflex is the question now before the TJUE. For residents of Portugal and the rest of the EU, the answer will determine not only what they learn about the past but also how transparently—and accountably—their governments act in the next health emergency.
